46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M…
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2…
46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M…
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2…
NORTHAMPTON, MA / ACCESS Newswire / December 17, 2025 / Originally published on Bristol Myers Squibb News & PerspectivesFor many…
12 early-career researchers will receive three years of support to carry out projects at the Institute for Systems Biology, University…
Partnership Brings AI-Powered Denial Prevention and Appeals Automation to 250-Provider GroupNEW YORK, Dec. 17, 2025 /PRNewswire/ -- Protego Health, a leading…
Smart Validation™ technology reduces clinical AI review time by 71%, helping health systems lower costs and accelerate patient follow-upDENVER, Dec.…
Revolutionary model represents a transformative step toward AI-powered virtual tissues, patient digital twins, and a new era of data-driven biomedical…
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing…